Get the Stockscreener App
1.44
8.86%
-0.14
After Hours:
1.44
Ventyx Biosciences Inc Stock (VTYX) Latest News
Ventyx Biosciences stock hits 52-week low at $1.41 amid market challenges - Investing.com India
Class Action Filed Against Ventyx Biosciences, Inc. (VTYX)April 30, 2024 Deadline to JoinContact Levi & Korsinsky - ACCESS Newswire
Ventyx Biosciences, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationVTYX - ACCESS Newswire
DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses of $100,000 to Contact the Firm - ACCESS Newswire
FINAL DEADLINE TUESDAY: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses to Contact the Firm - ACCESS Newswire
Shareholders that lost money on Ventyx Biosciences, Inc.(VTYX) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Ventyx Biosciences Faces Supply Chain Risks Amidst U.S.-China Tensions and Regulatory Challenges - TipRanks
Ventyx Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
VTYX SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Ventyx Biosciences, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
Ventyx Biosciences reports Q4 EPS (41c), consensus (55c) - TipRanks
Levi & Korsinsky Notifies Shareholders of Ventyx Biosciences, Inc. (VTYX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Ventyx Biosciences Reports Fourth Quarter and Full Year - GlobeNewswire
Can Ventyx's $252.9M Cash Cushion and 3 Upcoming Trial Readouts Excite Biotech Investors? - StockTitan
Ventyx Biosciences stock hits 52-week low at $1.57 By Investing.com - Investing.com Australia
Ventyx Biosciences stock hits 52-week low at $1.57 - Investing.com India
Investors who lost money on Ventyx Biosciences, Inc.(VTYX) should contact Levi & Korsinsky about pending Class ActionVTYX - ACCESS Newswire
Ventyx Biosciences (VTYX) to Release Earnings on Tuesday - Defense World
INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses of $100,000 to Contact the Firm - ACCESS Newswire
Ventyx Biosciences Inc expected to post a loss of 54 cents a shareEarnings Preview - TradingView
VTYX SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Ventyx Biosciences, Inc. Investors Can Join the Class Action Lawsuit! - ACCESS Newswire
Ventyx Biosciences Announces Presentation of Data from the - GlobeNewswire
Ventyx Biosciences’ VTX958 shows efficacy in Crohn’s Disease - TipRanks
Ventyx reports mixed results in Crohn's disease trial By Investing.com - Investing.com Australia
Ventyx reports mixed results in Crohn's disease trial - Investing.com India
Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 ... - The Bakersfield Californian
Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn’s Disease at ECCO 2025 - Yahoo Finance
SG Americas Securities LLC Cuts Stake in Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World
RSLS stock touches 52-week low at $2.57 amid market challenges - MSN
Ventyx Biosciences Inc (NASDAQ: VTYX): Overvalued In Comparison To Others? - Stocks Register
Ventyx Biosciences Inc (VTYX) expanding its growth trajectory ahead - SETE News
Ventyx Biosciences, Inc. (VTYX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
VTYX Shares Experience Decline in Value - Knox Daily
Does Ventyx Biosciences Inc (VTYX) offer a good opportunity for investors? - SETE News
Ventyx Biosciences Inc (VTYX) deserves closer scrutiny - US Post News
Ventyx Biosciences to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Marketscreener.com
Autoimmune Drug Developer Ventyx Takes Center Stage at Major Healthcare Conference - StockTitan
Recent Insider Activity Could Benefit Ventyx Biosciences Inc (VTYX) - Knox Daily
Investor’s Toolkit: Key Ratios for Assessing Ventyx Biosciences Inc (VTYX)’s Performance - The Dwinnex
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Sees Large Drop in Short Interest - MarketBeat
Ventyx Biosciences Inc (VTYX) Is On The Launchpad, Waiting For Long-Term Buyers. - Stocks Register
Class Action Filed Against Ventyx Biosciences, Inc. (VTYX) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
Ventyx Biosciences, Inc.'s (NASDAQ:VTYX) high institutional ownership speaks for itself as stock continues to impress, up 10% over last week - Simply Wall St
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Shares Acquired by Barclays PLC - Defense World
JPMorgan Chase & Co. Has $2.20 Million Holdings in Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World
What is HC Wainwright’s Estimate for VTYX FY2024 Earnings? - Defense World
HC Wainwright Analysts Increase Earnings Estimates for VTYX - MarketBeat
FY2029 Earnings Estimate for VTYX Issued By HC Wainwright - Defense World
Research Analysts Set Expectations for VTYX FY2029 Earnings - MarketBeat
Ventyx Biosciences Discloses Preliminary 2024 Financials and Pipeline Strategy - Defense World
Ventyx Biosciences highlights its 2025 pipeline strategy - Yahoo Finance
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Shares Sold by Jane Street Group LLC - Defense World
Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on its NLRP3 Inhibitor Portfolio - GlobeNewswire
Ventyx Biosciences advances NLRP3 inhibitor trials By Investing.com - Investing.com Canada
HC Wainwright Reaffirms Neutral Rating for Ventyx Biosciences (NASDAQ:VTYX) - MarketBeat
Ventyx Biosciences highlights 2025 pipeline strategy and provides clinical updates; shares rise - MSN
6.45%
1.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):